Review

Bio-Inorganic Layered Double Hydroxide Nanohybrids in Photochemotherapy: A Mini Review

N. Sanoj Rejinold 1*, Goeun Choi 1,2,3 and Jin-Ho Choy 1,4,5,6,*

1 Intelligent Nanohybrid Materials Laboratory (INML), Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan 31116, Korea
2 College of Science and Technology, Dankook University, Cheonan 31116, Korea
3 Department of Nanobiomedical Science and BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan 31116, Korea
4 Division of Natural Sciences, The National Academy of Sciences, Seoul 06579, Korea
5 Department of Pre-Medical Course, College of Medicine, Dankook University, Cheonan 31116, Korea
6 International Research Frontier Initiative (IRFI), Institute of Innovative Research, Tokyo Institute of Technology, Yokohama 226-8503, Japan
* Correspondence: jhchoy@dankook.ac.kr

Abstract: Clay-based bio-inorganic nanohybrids, such as layered double hydroxides (LDH), have been extensively researched in the various fields of biomedicine, particularly for drug delivery and bio-imaging applications. Recent trends indicate that such two-dimensional LDH can be hybridized with a variety of photo-active biomolecules to selectively achieve anti-cancer benefits through numerous photo/chemotherapies (PCT), including photothermal therapy, photodynamic therapy, and magnetic hyperthermia, a combination of therapies to achieve the best treatment regimen for patients that cannot be treated either by surgery or radiation alone. Among the novel two-dimensional clay-based bio-inorganic nanohybrids, LDH could enhance the photo-stability and drug release controllability of the PCT agents, which would, in turn, improve the overall phototherapeutic performance. This review article highlights the most recent advances in LDH-based two-dimensional clay-bio-inorganic nanohybrids for the aforementioned applications.

Keywords: inorganic bio-nanohybrids; clay nanoparticles; phototherapy; combined photochemotherapy; future directions

1. Introduction

Cancer therapies have advanced with the development of novel therapeutic models, such as personalized or precision medicine [1–4], but they continue to suffer from a considerable number of limitations. One of the most promising therapies, namely, phototherapy [5–7], has negligible side effects because of high selectivity and can be used to treat even deep-rooted tumors easily, such as liver tumors [8]. Phototherapy mainly consists of two types of therapies, namely, photothermal therapy (PTT) [9–11], which converts light to therapeutic heat energy, and photodynamic therapy (PDT) [12–14], which converts light to therapeutic reactive oxygen species (ROS) [15]. With the recent advances in nanotechnology, these therapeutic strategies are often combined to improve the overall efficacy of phototherapy. In addition, recent studies have utilized phototherapies in combination with chemotherapy, which is generally referred to as photochemotherapy (PCT). However, phototherapy suffers from a number of limitations, especially with regard to phototherapeutic agents [16]. In general, near-infrared (NIR) dyes or ROS generators are destabilized due to degradation. Researchers have attempted to improve the stability of phototherapeutic agents through encapsulation technologies, via polymers [17], liposomes [18], or micelles [19].

Although there are several nanotechnological tools available for phototherapy, they still suffer from their own disadvantages, such as low phototherapeutic stability and toxicity.
Recent studies have focused on the potential use of clay-based inorganic nanoparticles (NPs) in PCT applications. Clay NPs are clay minerals that are also referred to as sheet-silicates or phyllosilicates and form part of inorganic layered nanomaterials [20]. They have been used in healing agents [21] and as hemorrhage inhibitors [22]. Furthermore, they are used in pharmaceuticals as active ingredients in oral antacids, gastrointestinal protectors, and anti-diuretics, topically as dermatological protectors and anti-inflammatories [23], and in pharmaceutical preparations as disintegrants, diluents, binders, emulsifying agents, thickening agents, anticaking agents, flavor reservoirs, and the delivery modifiers of active agents [24].

Clay minerals are well known for their layered design, comprising polymeric sheets of silica (SiO₂) tetrahedra that are attached to octahedral sheets of Al, Mg, and Fe(O,OH)₆ [25]. These layered-type aluminosilicate minerals are formed during the chemical weathering of other silicate minerals that are present on the Earth’s surface [Ismadji et al., 2015]. It is difficult to define “clay minerals” because of the multiple meanings of the word “clay.” It can be used to denote a family of minerals or can pertain to a size fraction (0.98–3.9 mm) in soils and sediments. The latter is the most accepted definition. Generally, clay minerals are less than 2 µm in diameter [26]. Therefore, they have been described as micro- and nanocrystalline materials with a plate-like morphology because of the layered polyhedral arrangement in their structures [25].

Even though there are different types of clay NPs (such as anionic and cationic clays), anionic clay, in particular, the layered double hydroxides (LDHs) [27], has special advantages. Most importantly, the chemical composition of LDH clays can be controlled; therefore, the tunability for further functionalization is easier with cost-effective preparation technologies. In general, LDHs are a class of anion-exchange materials with a general chemical formula of [M₁⁺ₓM₃⁺ₙ(OH)₂]ₓ⁺[Aⁿ⁻ₓ/n]ₓ⁻·yH₂O (M: metal, A: anion). The isomorphic substitution of divalent metal cations (M¹⁺) in otherwise neutral brucite-like MІ⁺(OH)₂ sheets with trivalent cations (M₃⁺) produces cationic charges in the hydroxide layers. In the overall LDH structure, the intercalation of anions (Aⁿ⁻) in the interlamellar space compensates for the generated layer charges, as illustrated in Scheme 1.

![Scheme 1](image_url)

**Scheme 1.** Layered double hydroxides, built from sheets of [MІ⁺₁₋ₓM₃⁺ₙ(OH)₂]ˣ⁺ octahedral units intercalated with anions (large blue spheres). Each octahedron is composed of a metal cation (MІ⁺ or M₃⁺), coordinated with six OH⁻ ligands (small blue spheres).

The biggest advantage of clay NPs is their negligible toxicity at doses predominantly higher than with most other nanomaterials [28]. In addition, their degradation products are biocompatible and biodegradable, compared to most phototherapeutic agents [29]. Moreover, there is substantial evidence that confirms the potential effects of clay-based NPs in several cellular mechanisms, such as proliferation, differentiation, and regeneration [30].

In the case of phototherapy, the chemical stability of common phototherapeutic agents is critical [31]. Clay NPs have the potential to significantly improve the photostability of...
phototherapeutic agents in several physicochemical reactions, such as in intercalation and ion-exchange reactions, depending on the research strategy.

Although there are several clay-based NP review articles on drug delivery, a specific review on LDH-based hybrids and their PCT applications and recent trends has not been published. For example, Khatoon et al. (2020) and Dong et al. (2020) reviewed the general drug delivery applications of clay materials. However, these reviews did not discuss the use of clay materials in PCT applications [32]. In another review, various applications of two-dimensional (2D) nanomaterials, including photothermal therapy, water evaporation, thermochemical reactions, electrostatic lithography, catalysis, light-driven actuation, photothermal electrodes, energy storage, wearable heaters, and wound healing have been discussed [33]. A similar, previously published review (Chimene et al., 2015) also highlighted similar studies but only focused on general 2D nanomaterials for biomedical applications [34].

The application of clay-based NPs in PCT has several advantages because of their innate physicochemical functions, pore volume, internal surface properties, and structural and exchangeable cations [35,36]. The properties of these materials could be varied depending on the type of clay mineral and its structure. The basic chemistry of novel inorganic hybrid structures is also of great interest. Therefore, it is important to review the most recent developments in clay-based bio-inorganic nanohybrids acting as phototherapeutic and photochemical agents, along with their hybridization efficiency, since it impacts the therapeutic outcome. We believe that a fundamental as well as deep understanding would be highly beneficial to establish their existing issues or benefits so that scientists can improve their overall effects to maximize the therapeutic outcome.

The present review summarizes the recent trends in LDH-based bio-inorganic nanohybrids in terms of PCT applications and their chemical and biological aspects, along with future perspectives. We hope that bringing attention to these fundamental aspects of LDH-based clay hybrids will increase the number of prospective applications.

2. Inorganic Bio-Nanohybrids

2.1. Improvement of Photochemotherapy Using Inorganic Bio-Nanohybrids

The reason that clay-based NPs are selected for PCT applications lies in their exceptional biocompatibility, even at higher doses, and their pH specificity, which makes them suitable as efficient phototherapeutic delivery systems for effective cancer therapy. Most importantly, the phototherapeutic agents can be safely loaded, without photo-bleaching or sudden disintegration, into the interlayer nano-spaces of the clay NPs (Scheme 1).

2.2. Production of Inorganic Bio-Nanohybrids

Bio-inorganic nanohybrids can be produced through a “convergence” approach that incorporates the properties of the parent materials via a hybridization process. In brief, “convergence” is a strategical approach for coupling different materials to achieve better results than with their individual forms (Scheme 2). Although such approaches were initially applied in the field of energy research, they have since spread to the drug delivery and tissue engineering fields [37].

The key mechanism for producing bio-inorganic nanohybrids is by means of “2D lattice engineering” [38–44], where the 2D known host building blocks are stacked with the known inorganic, organic, or biomaterials needed for producing hybrid materials. The host materials used for studying hybrid materials are generally LDH and montmorillonite (MMT) NPs because of their excellent biocompatibility, tuneability, and pH sensitivity [45–50].
Scheme 2. Novel two-dimensional bio-nanohybridization strategies for photochemotherapy applications. (A: 2D clay-based building block that is primarily LDH; B: PTT agents; C-PDT agents and D: PTT, PDT, and chemo agents).

There are several lattice engineering reactions, such as intercalation, ion exchange, propping open, co-precipitation, exfoliation-reassembling, calcination reconstructing, and pillaring to make hybrid nanoparticles for phototherapy. In particular, PCT agents can be loaded in the interlayer nano-spaces of 2D lattices using the above-mentioned lattice engineering tools [51].

2.3. Photochemotherapy

Recently, PTT and PDT have been extensively researched for oncological applications. With nanotechnology-aided phototherapeutic agents, it is possible to improve the overall performance of PCT. However, PCT suffers from numerous problems, such as fast degradation and photo-bleaching. Therefore, stabilizing PCT agents inside the hybrids are of great relevance, which is critical to achieving an optimal therapeutic outcome. The interlayer nano-space and outer surface of clay NPs are highly functional since they are enriched with surface hydroxyl functional groups [35,52–60], which can easily be modified through covalent conjugation or hydrogen bonding. Some of the recent LDH-based inorganic hybrids are listed in Table 1.
Table 1. Various clay-based bio-inorganic nanohybrids in photothermal, photodynamic, photothermal/photodynamic, and chemo-combination therapies.

| Clay Hybrids                      | Phototherapeutic Agent or Chemo Drug Used | Applications                      | Physico/Chemical Characteristics                                                                 | Preparation Method                                                                 | Remarks                                                                 | Ref. |
|-----------------------------------|------------------------------------------|-----------------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------|------|
| Co-Fe-LDH                         | Co                                       | PTT, NIR, MRI, and PAI            | The TEM image of CoFe-LDH revealed nanosheets with a characteristic hexagonal morphology and a lateral size of $200 \pm 20$ nm. | Sintering at 200–800 °C under an Ar atmosphere                                      | Theranostic                                                           | [61] |
| B3int, DOX, and ICG loaded in LDH | ICG and DOX                              | PTT and Chemo                     | 80 nm sized LDH NPs                                                                         | LDNPs were prepared by a hydrothermal method followed by surface modification of the LDNPs with H$_2$N-PEG-NH$_2$. The targeting peptide B3int was introduced through an amide condensation reaction and finally, DOX and ICG were loaded using a physical adsorption method | Targeted cancer therapy and PTT                                      | [62] |
| Fe-LDH                            | Fe-LDH/DOX                               | MRI, PTT, and chemo               | Photothermal conversion efficiency of 45.67% with good stability and pH sensitivity          | Doping of ferrous ions into Fe-LDH and DOX loading through physical methods         | In vivo results on 4T1 tumor model proved its theranostic properties | [63] |
| DOX/ICG-CpG-LDH                   | ICG and DOX                              | PTT-Chemo-Immuo therapy           | The average particle size (DLS) increased from 84 nm (LDH) to 120 nm (BSA coated-LDH) at the BSA/LDH mass ratio of 5:2 | Solution mixing                                                                    | Theranosis toward breast cancers                                   | [64] |
| Isophthalic acid (IPA)/LDH nanohybrids | Isophthalic acid                         | PDT                               | The tapping mode AFM image demonstrates ~50 nm diameter and ~4 nm thickness of IPA/LDH, confirming the formation of ultrathin nanosheets Average hydrodynamic size for LDH is $52 \pm 2$ nm; the size increases to $150 \pm 7$, $184 \pm 3$, and $2633 \pm 685$ nm for Ce6-Pt(IV)/LDH with the Ce6-Pt(IV) of 0.81, 1.92, and 4.99, respectively | Co-precipitation method                                               | Combined PDT/chemotherapy                                         | [65] |
| Ce6/Pt(IV)-LDH                    | PDT/Chemo                                | Combined PDT and Chemo            | LDN was prepared by hydrothermal method and the Ce6 and Pt(IV) were loaded by anion-exchange reaction | Combined PDT and Chemo approach                                                   | Combined PDT and Chemo approach for cisplatin-resistant human cancer cells | [66] |
| Clay Hybrids      | Phototherapeutic Agent or Chemo Drug Used | Applications | Physico/Chemical Characteristics | Preparation Method | Remarks                                      | Ref. |
|------------------|----------------------------------------|--------------|----------------------------------|--------------------|----------------------------------------------|------|
| Fe-Mn-LDH        | Methylene blue                         | PTT/PDT      | It has 2D nanosheet structure with particle size of about 200 nm and thickness of 2.8 nm comprising 2–3 layers with good dispersibility in water and cell culture medium, with an average hydrated particle size of about 220 nm/zeta potential of $-25.4$ mV in water and exhibits good stability in both water and cell culture medium TEM images reveal that LI possessed a typical hexagonal plate-like morphology, with the particle lateral dimension in the range from 50 to 100 nm. After loading PTX-BSA/BSA and coating CCM, LIPC displayed a core–shell structure with a shell of 6–10 nm in length. | Co-precipitation method | Improved efficacy on U14 tumor model                  | [67] |
| LIPC[a] nanosheets | CCM, ICG, and PTX loaded with LDHs     | Combined PDT and Chemo | Hydrodynamic diameter and the zeta potential of Cu-LDH NPs in deionized water were measured to be $58.4 \pm 2.5$ nm and $37.0 \pm 0.6$ mV, respectively. The hybrids were in the range of ~200 nm. The Ce6 and silica coating on UCNPs@Ce6@mSiO2 (UCS) possesses an average diameter of 47 nm. The pure FeMn-LDH exhibits a 2D ultrathin structure and hexagon structure comprising several layers with the size of $\approx 100$ nm. After anchoring with UCSP NPs, it can be observed that UCSP can be anchored on the FeMn-LDH nanosheets with an increased size of $\approx 200$ nm with good monodispersity. The DLS particle sizes of UCSP, FeMn-LDH, and UCSP-LDH are 58.8, 130, and 230 nm, respectively with excellent stability in both water and cell culture medium after two days' standing. | Physical mixing         | Theranostic applications at lower dosage                  | [68] |
| ICG/Cu-LDH@BSA–DOX | ICG, Cu, and DOX                      | Dual phototherapy and imaging | Theranostic approach to treat colorectal cancers                   | Physical mixing | Theranostic approach to treat colorectal cancers                  | [69] |
| Fe-Mn-LDH        | Ce6 and mesoporous silica              | Trimodal therapy | The trimodal theranostic approach was validated on a U14-bearing tumor model                  | Physical mixing | The trimodal theranostic approach was validated on a U14-bearing tumor model                  | [70] |
Table 1. Cont.

| Clay Hybrids | Phototherapeutic Agent or Chemo Drug Used | Applications | Physico/Chemical Characteristics | Preparation Method | Remarks | Ref. |
|--------------|------------------------------------------|--------------|----------------------------------|--------------------|---------|------|
| d-Cu-LDH/ICG | d-Cu-LDH and ICG                         | Trimodal therapy | Cu-LDH, d-Cu-LDH, and LDH/ICG NPs showed typical plate-like morphology with almost the same particle size distribution with the average hydrodynamic particle size from $25.9 \pm 1.1$ to $38.8 \pm 1.8$ nm and zeta potential of around 34–35 mV | Intercalation of ICG into the interlayers of d-Cu-LDH | PTT and PDT-Chemo | [71] |

Abbreviations: LDH, layered double hydroxide; PTT, photothermal therapy; NIR, near-infrared; MRI, magnetic resonance imaging; PAI, photoacoustic imaging; B3int, arginine-tryptophan-(D-arginine)-asparagine-arginine; DOX, doxorubicin; ICG, indocyanine green; PDT, photodynamic therapy; CCM, cancer cell membrane; PTX, paclitaxel; LIPC, LDH-ICG/PTX-CCM; BSA, bovine serum albumin; CDT, chemodynamic therapy; PTT, photothermal therapy; IPA, Isophthalic acid; Ce6, chlorin e6; 4T1, breast cancer cell line derived from the mammary gland tissue of a mouse BALB/c strain; U14- squamous mouse carcinoma.
3. Photothermal Therapy and Photothermal/Chemotherapy

The PTT and PTT/chemotherapy (PTT-Chemo) applications of bio-inorganic nanohybrids have been extensively researched. Among them, the LDH-based applications are highlighted in the present review, with a focus on recent developments in the field (2020–2022).

3.1. PTT

Gold NPs, and gold nanorods (GNRs) in particular, have frequently been used for PTT applications [72–77]. The photothermal conversion efficiency ($\eta$) of GNRs are crucial. This can be tuned by increasing the aspect ratio and forming a core–shell structure with LDH NPs (Figure 1a). The interaction between GNRs and LDHs can induce electron deficiency on the surface of GNRs, generating therapeutic heat more efficiently. Therefore, the $\eta$ value of new hybrid NPs can reach 60% when irradiated at 808 nm of laser power, enhancing the $\eta$ value substantially. GNRs are coated with cetyl trimethyl ammonium bromide (CTAB), which can be replaced during the synthesis process. In addition, GNRs maintain a good dispersion in LDHs. This biocompatible core–shell composite GNRs@LDH can be applied to photothermal, antibacterial, tumor therapy, and bio-imaging capabilities [78].

Similarly, a series of novel CoFe-based PTT agents (CoFe-x) have been produced by heating CoFe-LDH nanosheets (NSs) at temperatures (x) between 200 and 800 °C under an argon environment. The produced hybrids differed based on their particle size, non-stoichiometry with cobalt deficiency, mixed electronic configurations, and band structures. Among them, the CoFe-500 product, which had the highest Co$^{2+}$ defect, was the most efficient PTT agent when irradiated under 808 nm of laser power. Experiments and density functional theory calculations confirmed that Co$^{2+}$ defects could modify the electronic structure of CoFe-x and could reduce the band gap, thereby increasing the non-radiative recombination rate and the PTT effects. In vitro and in vivo experimental results proved that CoFe-500 is an excellent PTT agent and can be traced using several imaging techniques, including NIR, magnetic resonance imaging (MRI), and photoacoustic (PA) techniques [61].

3.2. PTT-Chemotherapy

In PTT-Chemo approaches, the chemotherapy drug is either chemically or physically incorporated into the LDH NPs to achieve the maximum therapeutic efficacy with PTT. For example, a multifunctional LDH-nanohybrid system was developed for PTT-Chemo to specifically target the $\alpha_5\beta_3$ integrin receptors on cancer cells. Hence, arginine-tryptophan-(D-arginine)-asparagine-arginine (B3int) was loaded in the LDH through an EDC/NHS reaction, as shown in Figure 1b. The obtained product was further loaded with indocyanine green (ICG) and doxorubicin (DOX) to form the final product, LDH-PEG-B3int NPs, with approximately 19% drug loading efficiency and a remarkable $\eta$ value of approximately 25%. In addition, the drug release behavior was dependent on the pH and NIR power. In vitro and in vivo studies confirmed that the anti-tumor efficacy was significantly better for nanohybrids compared to their individual components. This result was experimentally determined using $\alpha_5\beta_3$ integrin-positive B16 (murine tumor cell line) [62].

Designing an effective theranostic system with tumor micro-environmental responsibility has several potential advantages, including better diagnosis and improved tumor homing characteristics, which would enhance the clinical output. To achieve this goal, 2D hybrids were synthesized by doping MgAl-LDH with functional ferrous ions, which were then loaded with DOX to form Fe-LDH/DOX NPs. The hybrid NPs had MRI (magnetic resonance imaging)-guided synergistic chemotherapy/PTT for breast cancer treatment. The doping of Fe-LDH/DOX with ferrous ions enabled a strong photo-induced heating ability with a high $\eta$ value of approximately 46%, which could be combined with DOX to have synergistic PTT and chemotherapeutic benefits. In addition, the in vitro pH-dependent degradation behavior and T2-weighted MRI effect revealed that the as-prepared Fe-LDH/DOX is sensitive to an acidic tumor microenvironment. Most importantly, the growth rate of tumors in 4T1-bearing mice was effectively suppressed after treatment with hybrid NPs. These results showed that the metal doping of LDH NPs could introduce a novel approach for fabricating an LDH NP-based nanotheranostics platform with advanced diagnostic and therapeutic performance [63].
on the surface of GNRs, generating therapeutic heat more efficiently. Therefore, the value of new hybrid NPs can reach 60% when irradiated at 808 nm of laser power, enhancing the value substantially. GNRs are coated with cetyl trimethyl ammonium bromide (CTAB), which can be replaced during the synthesis process. In addition, GNRs maintain a good dispersion in LDHs. This biocompatible core−shell composite GNRs@LDH can be applied to photothermal, antibacterial, tumor therapy, and bioimaging capabilities.

Figure 1. (a) Synthesis scheme of gold nanorods (GNR)@layered double hydroxide (LDH) (copyright from ACS-2019). (b) Novel two-dimensional (2D) bio-nanohybridization strategies for photochemotherapy applications. Schematic illustration of the synthesis of doxorubicin (DOX)-indocyanine green (ICG) and LDH-PEG-B3int((arginine-tryptophan-(D-arginine)-asparagine-arginine)) nanoparticles (copyright from Elsevier, 2019). (c) Illustration of nanohybrids as two-photon photosensitizers for $^1$O$_2$ generation. Schematic representation of the LDH host and five aromatic RTP guest species. Two-dimensional-confined long-lived triplet excitons can function as photosensitizers to achieve efficient $^1$O$_2$ generation under 808 nm near-infrared laser power (copyrights under Creative Commons Attribution 4.0 International License, Nature, 2018). (d) Overview of the strategy to co-deliver the Pt(IV) prodrug, DSCP (c,c,t-(diamminedichlorodisuccinato) Pt (IV), and the photosensitizer, Ce6 (chlorin e6), using LDH nanoparticles. (e) Synthetic steps involved in the development of trimodal photothermal therapy/photodynamic chemotherapy using d-Cu-LDH/ICG nanohybrids.
It is well known that both cancer recurrence and metastasis are global challenges. However, bimodular strategies, such as PTT-chemotherapies, are only successful in a limited number of cases. To improve these bimodular strategies, a multifaceted nanomedicine has been rationally developed by loading three FDA-approved therapeutics, namely, ICG (for PTT), DOX (for chemotherapy), and CpG (for immunotherapy) into the LDH NPs, to eliminate the recurrence and metastasis of invasive breast cancer (Scheme 3). According to an experimental analysis conducted on a 4T1 breast cancer model, the primary tumor tissues were completely eliminated. Therefore, no further recurrence of cancer and lung metastasis was observed. In addition, distant tumors were inhibited because of the improved immunity. Most importantly, the low drug dosage of FDA-approved drugs (ICG, DOX, and CpG) are the highlight of these nanohybrid systems and are expected to further improve the clinical outcome [64].

Scheme 3. Schematic representation of a multifunctional inodocyanin green (ICG)/Dox/DNA/CpG/BSA-LDH (IDCB)-layered double hydroxide (LDH) nanomedicine. (a) This hybrid nanomedicine was constructed via initial coating with bovine serum albumin (BSA) and then orderly loading with indocyanine green (ICG), the doxorubicin (DoX)/DNA prodrug, and CpG ODN (oligodeoxynucleotide) 1826. (b) IDCB-LDH, with 808 nm NIR irradiation, heats the tumor tissues and releases DoX at a temperature above 41 °C, yielding anti-tumor effects through efficient photothermal therapy and the subsequent CTX (chemotherapy), which then results in sufficient tumor antigens and stimulates the secretion of pro-tumor cytokines. The residual ICB-LDH in the tumor further acts as a nano-adjuvant and adsorbs the in situ-generated tumor antigens to mature and stimulate DCs (dendritic cells). (c) Mature DCs activate naïve T Cells in the dLNs (draining lymph nodes) and induce potent cytotoxic T lymphocytes (CTLs), namely, CD8+ T Cells. The CTLs subsequently migrate to the distant tumor tissues and the metastatic tumor nodules in the lung to eliminate the tumor cells. The CTLs increase, while the regulatory T cells decrease, in the distant and metastatic tumors (Reprinted/adapted with permission from Ref. [64]. Copyright 2019, American Chemical Society).
4. PDT and PDT/Chemotherapy

In recent years (2020–2022), PDT, whether used individually or combined with either PTT or chemotherapy, has not been widely explored. This is mainly due to the lack of proper lattice engineering strategies. However, there are only a few studies that have utilized LDH NPs as a base material for such applications. These studies will be explored in the following sections.

4.1. PDT

ROS (reactive oxygen species) have garnered considerable attention, not only in the field of catalysis research but also in biological studies because of their strong oxidizing properties [79–81]. In particular, the photosensitizers in PDT applications have four major properties, namely, the capability of generating singlet oxygen (\(1^\text{O}_2\)), long-wavelength absorption, good hydrophilicity, and biocompatibility. To achieve these properties in a single system, an NIR-responsive supramolecular photosensitizer-based isophthalic acid and LDH have been integrated as an efficient two-photon PDT nanohybrid system (Figure 1c). The \(1^\text{O}_2\) quantum yield of the nanohybrid reached 0.74. The in vitro anticancer efficacy on HeLa cells revealed that the approximate IC\(_{50}\) value was 0.153 \(\mu\text{g mL}^{-1}\). Furthermore, in vivo experiments on a HeLa tumor-bearing animal model confirmed that the nanohybrids were able to achieve deep tumor penetration when they were irradiated under 808 nm laser power, resulting in complete tumor eradication without any side effects. This proof-of-concept analysis clearly indicated that ultra-long-lived triplet excitons can contribute as two-photon-activated photosensitizers for efficient \(1^\text{O}_2\) production [65].

4.2. PDT/Chemotherapy

In this approach, chemotherapy drugs are combined with the PDT system to produce a desired nanohybrid, which is expected to improve the overall performance of the therapeutic regimen. For example, such a nanohybrid was made by assembling the ratiometric co-loading of Pt(IV) prodrug and Ce6 (PDT agent) into LDH NPs (Figure 1d). The as-made nanohybrids induced anti-cancer effects on cisplatin-resistant human cancer cells (A2780cisR cells) at nano-molar IC\(_{50}\) values via a combined PDT-Chemo mode. The in vitro experiments of Ce6-Pt(IV)/LDH on cisplatin-resistant and sensitive cells showed predominant apoptosis, compared to the untreated cells. Especially in A2780cisR cells, nanohybrids induced high early apoptotic cells (approximately 23%) and necrotic cells (approximately 39%) [66].

PDT-Chemo efficacy is mainly dependent on the endogenous \(\text{H}_2\text{O}_2\) concentration. However, it could be varied and is not effective for improved efficacy. Therefore, a self-supplied \(\text{H}_2\text{O}_2\)-enhanced PDT-Chemo strategy was achieved by engineering 2D sheet-like nanoparticles, in order to catalyze the molecular reactions. The nanocatalyst was produced by assembling ICG and Fenton reaction catalyst Fe\(^{2+}\) ions into two-dimensional ultrathin LDH NPs. Under NIR irradiation, ICG generates cytotoxic singlet oxygen (\(1^\text{O}_2\)), which cripples malignant cells, and superoxide radical (\(\text{O}_2^-\)), which is further converted to \(\text{H}_2\text{O}_2\) by reacting with intracellular superoxide dismutase (SOD). A sufficient self-supplied \(\text{H}_2\text{O}_2\), together with endogenous \(\text{H}_2\text{O}_2\), is then catalyzed by Fe\(^{2+}\) and released from the nanocatalyst to produce a sufficient amount of highly cytotoxic hydroxyl radicals (\(\text{OH}\)) to induce apoptosis in tumor cells. In vitro and in vivo evaluations demonstrate the remarkable performance of cascade nanocatalyst-mediated PDT-Chemo [51].

5. Simultaneous Photothermal/Photodynamic Therapy and Chemotherapy

5.1. Photothermal/Photodynamic

It has been suggested that rod/plate-like nanomaterials with an appropriate size exhibit higher and longer-term lysosomal enrichment because the shape plays a notable role in the nanomaterial transmembrane process and subcellular behaviors. Biodegradable LDH-based nanohybrids with CuS nanocomposites (LDH-CuS NCs) were rationally developed through the in situ growth of CuS nanodots on LDH nanoplates. These LDH-CuS NCs
exhibited high photothermal conversion, NIR-induced chemodynamics, and PDT efficacies, and real-time in vivo photoacoustic imaging (PAI) of the entire tumor was achieved. In addition, the lysosomal internalized LDH-CuS NCs resulted in higher subcellular ROS in situ, leading to lysosomal membrane permeabilization (LMP) pathway-associated cell death, both in vitro and in vivo [82].

Previously, an iron-manganese LDH NS (200 nm in size) was synthesized to achieve combined PTT/PDT for effective cancer therapy. Methylene blue was loaded into the LDH NPs to enhance the catalase-like activity, which could help the NSs to decompose H$_2$O$_2$ to O$_2$ and overcome tumor hypoxia through O$_2$-dependent PDT. The experimental results indicated that these nanohybrids were nearly able to eliminate the whole tumor, as evidenced by the in vivo animal experiments on U14 tumors (squamous mouse carcinoma) [67].

5.2. PTT-PDT-Chemotherapy

Although multi-modal therapies can improve the overall efficacy by stimulating the immune community, low tumor accumulation, along with easy immune clearance of the anti-tumor agents, are still difficult to achieve. As cancer cell membranes (CCMs) can have homologous tumor targeting [83], further improvements can be made using multi-modal therapy by complementing the limitations of individual therapeutic modes. In addition, the intracellular uptake of cancer cells can be controlled by photo-induced hyperthermia. CCM-modified-ICG and Abraxane (bovine serum albumin (BSA)-coated paclitaxel (PTX) formulation) were loaded on the LDH NSs to form LIPC NSs (LDH-ICG/PTX-CCM NSs) for the targeted photochemotherapy of colorectal carcinoma (CRC). The CCM-modified NSSs induced effective targeted toxicity and were greatly improved upon laser exposure, synergizing CRC apoptosis. CCM cloaking reduced the uptake of LDH NSs by HEK 293T cells and macrophages, implying mitigation of the side effects and the immune clearance, respectively. The in vivo data further demonstrated that LIPC NSs improved the drug accumulation in tumor tissues and significantly inhibited tumor proliferation under laser irradiation at very low therapeutic doses (1.2 and 0.6 mg/kg of ICG and PTX-BSA, respectively), without severe organ damage. This study clearly demonstrated the importance of CCM coatings on the bio-inorganic nanohybrids, which is critical in achieving the targeted drug delivery and immune-escaping characteristics that can eventually enhance the overall efficacy of drug delivery systems. Furthermore, CCM modifications can also improve the overall hyperthermia by enhancing the cancer cellular uptake of LIPC NSs on cancer cells and improving the overall multi-modal cancer therapy [68].

In a previous study, a trifunctional LDH nanohybrid for the combined photochemotherapy (PTT/PDT and chemotherapy) of skin cancer at very low therapeutic doses was explored. This nano-system (ICG/CuLDH@BSA−DOX) was composed of an acid-responsive BSA−DOX prodrug and ICG-intercalated Cu-doped LDH NPs. Thus, ICG/CuLDH@BSA−DOX could have pH-dependent DOX release. In addition, a combinatorial PTT/PDT was achieved under 808 nm laser exposure, inducing dermal cancer apoptosis. In vivo studies confirmed that the ICG/Cu-LDH@BSA−DOX nanohybrid particles were able to satisfactorily ablate the tumor cells when irradiated with a single course of low dosage (DOX: 0.175 mg kg$^{-1}$, Cu: 0.5 mg kg$^{-1}$, and ICG: 0.25 mg kg$^{-1}$) at an 808-nm laser condition of low power at 0.3 W cm$^{-2}$ for 2 min (Scheme 4). This study clearly indicates that rationally designed anti-cancer nanohybrids would be an efficient combination with phototherapy to minimize severe toxic effects and could be useful for translational medicines [69].

In another study, tumor microenvironment (TME)-sensitive nanohybrids based on FeMn-LDH were developed for simultaneous PTT/PDT and chemotherapy applications under single laser irradiation and a power of 980 nm and 0.72 W cm$^{-2}$, respectively, for 5 min. Mesoporous silica and chlorin e6 (Ce6) were covalently coated on the LDH NPs as up-conversion NPs (UCSP) for multimodal imaging-directed cancer therapy. In an acidic environment, FeMn-LDH can be dissolved and will release Fe$^{3+}$ and Mn$^{2+}$ ions to initiate a Fenton-like reaction enabling PTT/PDT/Chemotherapy, along with MRI. Meanwhile,
Fe$^{3+}$ can catalytically decompose hydrogen peroxide ($2\text{H}_2\text{O}_2$) into oxygen ($\text{O}_2$) and water ($2\text{H}_2\text{O}$), enhancing the PDT guided by UCSP. As a representative non-invasive imaging probe, the up-conversion luminescence can be recovered after the decomposition of FeMn-LDH and can provide high-resolution luminescence for pinpointed PDT. Additionally, the PTT effects of FeMn-LDH can enhance the PDT-Chemo effects. Simultaneous therapy, along with multimodal imaging, can realize the integration of diagnosis and treatment for the efficient theranostic approach, as experimentally proven on the U14 (squamous mouse carcinoma)-bearing tumor model [70].

**Scheme 4.** Schematic illustration of a multifunctional indocyanine green (ICG)/Cu-layered double hydroxide (LDH)@BSA–doxorubicin (DOX) nanomedicine. (a) Hybrid LDH nanoparticles constructed by making Cu-LDH, loading ICG, and then coating with BSA/BSA–DOX. (b) Mice bearing B16F0 tumors are intravenously injected with ICG/Cu-LDH@BSA–DOX and exposed to 808-nm laser irradiation (0.3 W cm$^{-2}$ for 2 min) after 24 h injection, at considerably lower doses (DOX: 0.175 mg kg$^{-1}$, Cu: 0.5 mg kg$^{-1}$, and ICG: 0.25 mg kg$^{-1}$) than those usually used. (c) BSA/BSA–DOX-coated ICG/Cu-LDH nanoparticles efficiently accumulate in the tumor site via the EPR effect and facilitate the uptake of tumor cells via the clathrin-mediated endocytosis pathway. In the late endosome, LDH nanoparticles that were neutralized with pumped-in H$^+$ ions led to an increased number of Mg$^{2+}$, Al$^{3+}$, and Cl$^-$ ions. An increase in the ionic strength within the endosome drove the water molecules into the endosome, resulting in the osmotic swelling of the endosome and the eventual release of the residual LDH nanoparticles into the cytoplasm. Once internalized by B16F10 cancer cells, ICG/Cu-LDH@BSA–DOX releases therapeutic DOX in response to an acidic environment (pH 5.0–6.5), which synergizes with near-infrared irradiation-induced photothermal therapy (PTT)/photodynamic therapy (PDT) to enable tumor apoptosis. (d) The mechanism of pH-triggered DOX release involves amide bond cleavage under a mildly acidic microenvironment of tumor tissues and cells. (Reprinted/adapted with permission from Ref. [69]. 2021, American Chemical Society).

Similarly, LDH NP-based trimodal inorganic nanohybrids were produced for an efficient breast cancer therapy without any conventional anticancer drugs. NIR-sensitive ICG molecules were integrated on Cu-LDH NPs, which were further acid-etched to induce more Cu defects in the LDH lattice (d-Cu-LDH/ICG). This, in turn, induced tri-
modal therapy (PTT/PDT/Chemotherapy) under a single laser source (808 nm laser) at a low power irradiation of 2.5 W cm$^{-2}$ for 5 min, at low dosages of 2.5 and 5 mg kg$^{-1}$ (Figure 1e). The as-made nanohybrids could enhance both PTT and PDT simultaneously, while PDT-Chemo was achieved with the same nanohybrid system, as confirmed through the in vitro and in vivo experiments on 4T1 cancer cells and a tumor model, respectively. Moreover, d-Cu-LDH/ICG NPs generate hydroxyl radicals in the presence of H$_2$O$_2$ as Fenton catalysts, which were further improved upon by Cu(II) reduction with glutathione and temperature elevation. As a result, these nanohybrids were able to suppress 4T1 cell proliferation and showed effective inhibition of tumor growth in vivo, via the multifaceted PTT/PDT/chemotherapy approach under mild laser irradiation. This study clearly indicates that the rational synthesis of defects in LDH nanohybrids would be highly beneficial in combinatorial approaches, without the need for conventional anti-cancer agents. In addition, due to the combined actions of PTT and PDT, complete tumor eradication can be guaranteed, if treated in the early stages of the disease [70].

6. Future Perspectives and Conclusions

Biocompatibility and therapeutic efficacy are the major criteria for any biomedical products, along with affordable prices. Of course, LDH-based hybrids could be an easily reproducible material for PCT applications, as the chemical compositions and functionalization are easy to be controlled than many other clay NPs. In addition, from the various literature studies, it is clear that LDH-based bio-nanohybrids hold good biocompatibility and biodegradability. In a reported in vivo study, it was proposed that intramuscularly implanted LDH tablets in the rat abdominal wall could stay there with no notable toxicity. The tablets were composed of chloride ions intercalated into LDH of magnesium/aluminum (Mg$_2$Al-Cl) and zinc/aluminum (Zn$_2$Al-Cl), respectively. Post-implantation studies using histology assessment reveal no fibrous capsule development around the implanted sites for both types of LDHs. In addition, there were no inflammatory reactions post-implantation with these biomaterials. The sidestream dark field imaging analysis (which is usually used for real-time monitoring of the microcirculation in tissues) confirmed a good microcirculatory network around the LDH-implanted sites and were well maintained, with good blood flow, without enhancing the the leukocyte’s endothelial adhesion. Four weeks of study revealed that the Mg$_2$Al-Cl tablet promoted mainly type-I collagen, whereas the Zn$_2$Al-Cl greatly enhanced type-III collagen [84]. However, when considering the LDH-hybrids, especially when integrating them with novel materials for PCT application, it is necessary to clearly understand their long-term toxicity and pharmacodynamics for the benefit of clinical applications.

We suggest that LDH-based photochemical agents are the most cost-effective photosensitive anticancer nanohybrids. However, there are many challenges, as aforementioned, that still need to be overcome before these techniques can be commercially used. Clay-based inorganic NPs are, in general, safe and biocompatible. However, their hybrids could contain a certain degree of toxicity, especially when they are used for long-term applications. Therefore, the toxicity of newly developed LDH-based hybrids should be thoroughly verified.

The stability of colloidal nanohybrids is also critical, especially in the context of injectable formulations and can be highly dependent on the solvents and media used. At present, it is hard to validly report the “stability” of nanohybrids from the literature, as there are not many solid facts from such studies using various conditions, such as simulating body fluid (SBF) or cell culture media, etc. Future studies must be more focused to cast light on the colloidal stability of novel LDH nanohybrids for injectable PCT applications.

Another aspect is utilizing LDH hybrids for scaffold-based PTT for breast cancer bone metastasis. In general, surgical procedures for breast cancer bone metastases have numerous limitations, such as bone defects and tumor recurrence. In such a case, a nacre-mimetic, mechanically stable graphene oxide/layered double hydroxide/chitosan (GO/LDH/CS) layered scaffold with anti-tumor and pro-osteogenesis activities could be
beneficial. When exposed to a NIR laser, the local temperature around the scaffolds could rise to 52 °C within 2 min, triggering anti-tumor activity via apoptosis, through increasing caspase-3 expression. Additionally, GO nanosheets and Mg^{2+} ions could enhance the pro-osteogenesis activity of GO/LDH/CS layered scaffolds. Twelve weeks after scaffold implantation, it was found that the layered macropores in the scaffolds were filled with extracellular matrix and bone tissues. Hence, the integration of a nacre-mimetic architecture and biofunctional materials could be a novel strategy to treat intractable disease-related bone defects [85].

Although LDH hybrids have recently begun to be used in PCT applications, this suggests that it takes time for their commercial applications to be realized. Consequently, it is difficult to draw any conclusions about the clinical aspects at the moment. However, we hope that in the near future, there will be new studies emerging in the LDH-based PCT research fields, with more insights on chemical and biological fundamentals and the toxicological aspects.

In conclusion, we have reviewed recent LDH-based nanohybrids for PCT applications, suggesting that such hybrids may be a potential therapeutic strategy for many deep-seated cancers. Such nanohybrids are possible due to the unique chemical nature of LDH and the tunable chemical composition, interlayer nanospace, and ease of surface modification of LDH. However, more studies (pharmacokinetics, biodistribution, organ toxicity, and histological evaluation) are necessary to understand their toxicological aspects for them to be fully utilized in further applications.

**Author Contributions:** Conceptualization, N.S.R., G.C. and J.-H.C.; methodology, N.S.R., G.C. and J.-H.C.; software, N.S.R., G.C. and J.-H.C.; validation, N.S.R., G.C. and J.-H.C.; writing—original draft preparation, N.S.R., G.C. and J.-H.C.; writing—review and editing, N.S.R., G.C. and J.-H.C.; visualization, N.S.R., G.C. and J.-H.C.; project administration and funding acquisition, J.-H.C. and G.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. 2020R1I1A2074844), by the NRF grant funded by the Korean government (MSIT) (No. 2022R1F1A1076459), and under the framework of the International Cooperation Program managed by NRF (2017K2A92A10013104).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Ciardiello, F.; Ciardiello, D.; Martini, G.; Napolitano, S.; Tabernero, J.; Cervantes, A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA A Cancer J. Clin. 2022, 72, 372–401. [CrossRef] [PubMed]
2. Karagiannis, D.; Rampias, T. Cancer Evolution in Precision Medicine Era. Cancers 2022, 14, 1885. [CrossRef] [PubMed]
3. Curtin, M.; Somayaji, D.; Dickerson, S.S. Precision Medicine Testing and Disparities in Health Care for Individuals With Non-Small Cell Lung Cancer: A Narrative Review. Oncol. Nurs. Forum 2022, 49, 257–272. [CrossRef] [PubMed]
4. Goulder, A.; Gaillard, S.L. Molecular classification of endometrial cancer: Entering an era of precision medicine. J. Gynecol. Oncol. 2022, 33, e47. [CrossRef]
5. Singh, R.; Yang, X. A 3D finite element model to study the cavitation induced stresses on blood–vessel wall during the ultrasound-only phase of photo-mediated ultrasound therapy. AIP Adv. 2022, 12, 045020. [CrossRef]
6. Liu, J.; Liu, H.; Jia, Y.; Tan, Z.; Hou, R.; Lu, J.; Luo, D.; Fu, X.; Wang, L.; Wang, X. Glucose-sensitive delivery of tannic acid by a photo-crosslinked chitosan hydrogel film for antibacterial and anti-inflammatory therapy. J. Biomater. Sci. Polym. Ed. 2022, 33, 1644–1663. [CrossRef]
7. Qin, Y.; Yu, Y.; Fu, J.; Wang, M.; Yang, X.; Wang, X.; Paulus, Y.M. Photo-mediated ultrasound therapy for the treatment of retinal neovascularization in rabbit eyes. Lasers Surg. Med. 2022, 54, 747–757. [CrossRef] [PubMed]
8. Zou, H.; Wang, F.; Zhou, J.; Liu, X.; He, Q.; Wang, C.; Zheng, Y.-W.; Wen, Y.; Xiong, L. Application of photodynamic therapy for liver malignancies. J. Gastrointest. Oncol. 2020, 11, 431–442. [CrossRef] [PubMed]
35. Rejinold, N.S.; Piao, H.; Choi, G.; Jin, G.-W.; Choy, J.-H. Niclosamide-Exfoliated Anionic Clay Nanohybrid Repurposed as an Antiviral Drug for Tackling Covid-19; Oral Formulation with Tween 60/Eudragit S100. *Clays Clay Miner.* **2021**, *69*, 533–546. [CrossRef] [PubMed]

36. Piao, H.; Rejinold, N.S.; Choi, G.; Pei, Y.-R.; Jin, G.-W.; Choy, J.-H. Niclosamide encapsulated in mesoporous silica and geopolymer: A potential oral formulation for COVID-19. *Microporous Mesoporous Mater.* **2021**, *326*, 113194. [CrossRef] [PubMed]

37. Freag, M.S. Protein-inorganic Nanohybrids: A Potential Symbiosis in Tissue Engineering. *Curr. Drug Targets* **2018**, *19*, 1897–1904. [CrossRef] [PubMed]

38. Shinde, R.B.; Padalkar, N.S.; Sadavar, S.V.; Kale, S.B.; Magdum, V.V.; Chitare, Y.M.; Kulkarni, S.P.; Patil, U.M.; Parale, V.G.; Park, H.-H.; et al. 2D–2D lattice engineering route for intimately coupled nanohybrids of layered double hydroxide and potassium hexaniobate: Chemiresistive SO2 sensor. *J. Hazard. Mater.* **2022**, *432*, 128734. [CrossRef]

39. Cao, X.; Huang, A.; Liang, C.; Chen, H.-C.; Han, T.; Lin, R.; Peng, Q.; Zhuang, Z.; Shen, R.; Chen, H.M.; et al. Engineering Lattice Disorder on a Photocatalyst: Photochromic BiOBr Nanosheets Enhance Activation of Aromatic C–H Bonds via Water Oxidation. *J. Am. Chem. Soc.* **2022**, *144*, 3386–3397. [CrossRef]

40. Wang, C.; Zhai, P.; Xia, M.; Wu, Y.; Zhang, B.; Li, Z.; Ran, L.; Gao, J.; Zhang, X.; Fan, Z.; et al. Engineering Lattice Oxygen Activation of Iridium Clusters Stabilized on Amorphous Bimetal Borides Array for Oxygen Evolution Reaction. *Angew. Chem. Int. Ed.* **2021**, *60*, 27126–27134. [CrossRef]

41. Zhang, W.; Qiu, F.; Li, Y.; Zhang, R.; Liu, H.; Li, L.; Xie, J.; Hu, W. Lattice Defect Engineering Enables Performance-Enhanced MoS2 Photodetection through a Paraelectric BaTiO3 Dielectric. *ACS Nano* **2021**, *15*, 13370–13379. [CrossRef]

42. Kim, N.; Gu, T.-H.; Shin, D.; Jin, X.; Shin, H.; Kim, M.G.; Kim, H.; Hwang, S.-J. Lattice Engineering to Simultaneously Control the Defect/Stacking Structures of Layered Double Hydroxide Nanosheets to Optimize Their Energy Functionabilities. *ACS Nano* **2021**, *15*, 8306–8318. [CrossRef]

43. Stathi, P.; Solakidou, M.; Deligiannakis, Y. Lattice Defects Engineering in W-, Zr-doped BiVO4 by Flame Spray Pyrolysis: Enhancing Photocatalytic O2 Evolution. *Nanomaterials* **2021**, *11*, 501. [CrossRef]

44. Lai, Y.-T.; Wang, T.; O’Dell, S.; Louder, M.K.; Schön, A.; Cheung, C.S.F.; Chuang, G.-Y.; Druz, A.; Lin, B.; McKee, K.; et al. Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry. *Nat. Commun.* **2019**, *10*, 47. [CrossRef]

45. Kim, M.H.; Hur, W.; Choi, G.; Min, H.S.; Choi, T.H.; Bin Choy, Y.; Choy, J.-H. Theranostic Bioabsorbable Bone Fixation Plate with Drug-Layered Double Hydroxide Nanohybrids. *Adv. Health Mater.* **2016**, *5*, 2765–2775. [CrossRef]

46. Choy, J.-H.; Choi, G.; Huiyan, P.; A Alothman, Z.; Vinu, A.; Yun, C.-O. Anionic clay as the drug delivery vehicle: Tumor targeting function of layered double hydroxide-methotrexate nanohybrid in C33A orthotopic cervical cancer model. *Int. J. Nanomed.* **2016**, *11*, 337–348. [CrossRef] [PubMed]

47. Lv, F.; Xu, L.; Zhang, Y.; Meng, Z. Layered Double Hydroxide Assemblies with Controllable Drug Loading Capacity and Release Behavior as well as Stabilized Layer-by-Layer Polymer Multilayers. *ACS Appl. Mater. Interfaces* **2015**, *7*, 19104–19111. [CrossRef] [PubMed]

48. Tuncelli, G.; Ay, A.N.; Zümreoglu-Karan, B. 5-Fluorouracil intercalated iron oxide@layered double hydroxide core-shell nanocomposites with isotropic and anisotropic architectures for shape-selective drug delivery applications. *Mater. Sci. Eng. C* **2015**, *55*, 562–568. [CrossRef]

49. Oh, J.-M.; Park, C.-B.; Choy, J.-H. Intracellular Drug Delivery of Layered Double Hydroxide Nanoparticles. *J. Nanosci. Nanotechnol.* **2011**, *11*, 1632–1635. [CrossRef]

50. Choy, J.-H.; Jung, J.-S.; Oh, J.-M.; Park, M.; Jeong, J.; Kang, Y.-K.; Han, O.-J. Layered double hydroxide as an efficient drug reservoir for folate derivatives. *Biomaterials* **2004**, *25*, 3059–3064. [CrossRef]

51. Guo, Z.; Xie, W.; Zhang, Q.; Lu, J.; Ye, J.; Gao, X.; Xu, W.; Fahad, A.; Xie, Y.; Wei, Y.; et al. Photoactivation-triggered in situ self-supplied H2O2 for boosting chemodynamic therapy via layered double Hydroxide-mediated catalytic cascade reaction. *Chem. Eng. J.* **2022**, *446*, 137310. [CrossRef]

52. Piao, H.; Choi, G.; Jin, X.; Hwang, S.-J.; Song, Y.J.; Cho, S.-P.; Choy, J.-H. Monolayer Graphitic Carbon Nitride as Metal-Free Catalyst with Enhanced Performance in Photo- and Electro-Catalysis. *Nano-Micro Lett.* **2022**, *14*, 55. [CrossRef]

53. Choi, G.; Rejinold, N.S.; Piao, H.; Choy, J.-H. Inorganic–inorganic nanohybrids for drug delivery, imaging and photo-therapy: Recent developments and future scope. *Chem. Sci.* **2021**, *12*, 5044–5063. [CrossRef]

54. Choi, G.; Piao, H.; Rejinold, N.; Yu, S.; Kim, K.-Y.; Jin, G.-W.; Choy, J.-H. Hydrotalcite–Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections. *Pharmaceuticals* **2021**, *14*, 486. [CrossRef]

55. Yu, S.; Piao, H.; Rejinold, N.; Jin, G.; Choi, G.; Choy, J.-H. Niclosamide–Clay Intercalate Coated with Nonionic Polymer for Enhanced Bioavailability toward COVID-19 Treatment. *Polymers* **2021**, *13*, 1044. [CrossRef]

56. Choi, G.; Choy, J.-H. Recent progress in layered double hydroxides as a cancer theranostic nanoplatform. *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* **2021**, *13*, e1679. [CrossRef]

57. Park, C.G.; Choi, G.; Kim, M.H.; Kim, S.-N.; Lee, H.; Lee, N.K.; Bin Choy, Y.; Choy, J.-H. Brimonidine–montmorillonite hybrid formulation for topical drug delivery to the eye. *J. Mater. Chem. B* **2020**, *8*, 7914–7920. [CrossRef] [PubMed]

58. Pei, Y.-R.; Yang, J.-H.; Choi, G.; Choy, J.-H. A geopolymer route to micro- and meso-porous carbon. *RSC Adv.* **2020**, *10*, 6814–6821. [CrossRef]
59. Piao, H.; Kim, M.H.; Cui, M.; Choi, G.; Choy, J.-H. Alendronate-Anionic Clay Nanohybrid for Enhanced Osteogenic Proliferation and Differentiation. *J. Korean Med. Sci.* 2019, 34, e37. [CrossRef]

60. Choi, G.; Eom, S.; Vinu, A.; Choy, J.-H. 2D Nanostructured Metal Hydroxides with Gene Delivery and Theranostic Functions; A Comprehensive Review. *Chem. Rev.* 2018, 18, 1033–1053. [CrossRef]

61. Wang, L.; Xu, S.-M.; Yang, X.; He, S.; Guan, S.; Waterhouse, G.I.N.; Zhou, S. Exploiting Co Defects in CoFe-Layered Double Hydroxide (CoFe-LDH) Derivatives for Highly Efficient Photothermal Cancer Therapy. *ACS Appl. Mater. Interfaces* 2020, 12, 54916–54926. [CrossRef]

62. Ye, Y.; Bremer, D.H.; Zhang, H.; Chen, X.; Lou, J.; Zhu, L.-M. Functionalized layered double hydroxide nanoparticles as an intelligent nanoplatform for synergistic photothermal therapy and chemotherapy of tumors. *Colloids Surf. B Biointerfaces* 2022, 210, 112261. [CrossRef]

63. Guo, Z.; Xie, W.; Lu, J.; Guo, X.; Chi, Y.; Wang, D.; Takuya, N.; Xu, W.; Ye, J.; Liu, X.; et al. Ferrous ions doped layered double hydroxide: Smart 2D nanotheranostic platform with imaging-guided synergistic chemo/photothermal therapy for breast cancer. *Biomater.* 2021, 9, 5928–5938. [CrossRef]

64. Zhang, L.-X.; Sun, X.-M.; Xu, Z.P.; Liu, R.-T. Development of Multifunctional Clay-Based Nanomedicine for Elimination of Primary Invasive Breast Cancer and Prevention of Its Lung Metastasis and Distant Inoculation. *ACS Appl. Mater. Interfaces* 2019, 11, 35566–35576. [CrossRef]

65. Gao, R.; Mei, X.; Yan, D.; Liang, R.; Wei, M. Nano-photosensitizer based on layered double hydroxide and isophthalic acid for singlet oxygenation and photodynamic therapy. *Nat. Commun.* 2018, 9, 2978. [CrossRef]

66. Wang, Z.; Ma, R.; Yan, L.; Chen, X.; Zhu, G. Combined chemotherapy and photodynamic therapy using a nanohybrid based on layered double hydroxides to conquer cisplatin resistance. *Chem. Commun.* 2015, 51, 11587–11590. [CrossRef] [PubMed]

67. Ruan, Y.; Jia, X.; Wang, C.; Zhen, W.; Jiang, X. Mn–Fe layered double hydroxide nanosheets: A new photothermal nanocarrier for O2-evolving phototherapy. *Chem. Commun.* 2016, 52, 11729–11732. [CrossRef] [PubMed]

68. Wang, J.; Sun, L.; Liu, J.; Sun, B.; Li, L.; Xu, Z.P. Biomimetic 2D layered double hydroxide nanocomposites for hyperthermia-facilitated homologous targeting cancer photo-chemotherapy. *J. Nanobiotechnol.* 2021, 19, 351. [CrossRef] [PubMed]

69. Liu, J.; Sun, L.; Li, L.; Zhang, R.; Xu, Z.P. Synergistic Cancer Photochemotherapy via Layered Double Hydroxide-Based Trimodal Nanomedicine at Very Low Therapeutic Doses. *ACS Appl. Mater. Interfaces* 2021, 13, 7115–7126. [CrossRef] [PubMed]

70. Jia, T.; Wang, Z.; Sun, Q.; Dong, S.; Xu, J.; Zhang, F.; Feng, L.; He, F.; Yang, D.; Yang, P.; et al. Intelligent Fe–Mn Layered Double Hydroxides Nanosheets Anchored with Upconversion Nanoparticles for Oxygen-Elevated Synergetic Therapy and Bioimaging. *Small* 2020, 16, e2001343. [CrossRef]

71. Sun, L.; Wang, J.; Liu, J.; Li, L.; Xu, Z.P. Creating Structural Defects of Drug-Free Copper-Containing Layered Double Hydroxide Nanoparticles to Synergize Photothermal/Photodynamic/Chemodynamic Cancer Therapy. *Small Struct.* 2020, 2, 2000112. [CrossRef]

72. Liao, S.; Yue, W.; Cai, S.; Tang, Q.; Lu, W.; Huang, L.; Qi, T.; Liao, J. Improvement of Gold Nanorods in Photothermal Therapy: Recent Progress and Perspective. *Front. Pharmacol.* 2021, 12, 664123. [CrossRef]

73. Thorve, S.M.; Awad, N.T.; Nair, J.P.; Waghmare, S.R.; Gp, G.; Nair, G.S. Comparison in Outcome of Patients with Post TB-Destroyed Lung and COPD Admitted with Respiratory Failure. *J. Assoc. Physicians India* 2007, 53, 25–52. [CrossRef]

74. Gupta, H.; Pfeiffer, J.; Gopinath, S.; Muthukumar, R.; Ito, C.-I.; Watanabe, S.; Butikhu, D.S. Acute cholelitic intestinal obstruction. *Khumgas* 2007, 2, 51–52.

75. Gföbert, H. Medical, social and economic state of German thermalism. *La Press. Therm. Clim.* 1969, 106, 178–180.

76. Ma, K.; Li, Y.; Wang, Z.; Chen, Y.; Zhang, X.; Chen, C.; Yu, H.; Huang, J.; Yang, Z.; Wang, X.; et al. Core–Shell Gold Nanorod@Layered Double Hydroxide Nanomaterial with Highly Efficient Photothermal Conversion and Its Application in Antibacterial and Tumor Therapy. *ACS Appl. Mater. Interfaces* 2019, 11, 29630–29640. [CrossRef] [PubMed]

77. Ulkuňa, H.; Oţzelık, B.; Güler, I. Designing and application of a new medical instrument sterilization system using reactive oxygen species. *Rev. Sci. Instruments* 2021, 92, 114105. [CrossRef]

78. Kovacic, P.; Somanathan, R. Ototoxicity and noise trauma: Electron transfer, reactive oxygen species, cell signaling, electrical effects, and protection by antioxidants: Practical medical aspects. *Med. Hypotheses* 2008, 70, 914–923. [CrossRef] [PubMed]

79. Kovacic, P. Unifying mechanism for bacterial cell signalers (4,5-dihydroxy-2,3-pentanedione, lactones and oligopeptides): Electron transfer and reactive oxygen species. Practical medical aspects. *Med. Hypotheses* 2007, 69, 1105–1110. [CrossRef]

80. Liu, C.-G.; Tang, H.-X.; Zheng, X.; Yang, D.-Y.; Zhang, Y.; Zhang, J.-T.; Kankala, R.K.; Wang, S.-B.; Liu, G.; Chen, A.-Z. Near-Infrared-Activated Lysosome Pathway Death Induced by ROS Generated from Layered Double Hydroxide-Copper Sulfide Nanocomposites. *ACS Appl. Mater. Interfaces* 2020, 12, 40673–40683. [CrossRef]

81. Liu, L.; Chen, Y.; Liu, C.; Yan, Y.; Yang, Z.; Chen, X.; Liu, G. Effect of Extracellular Matrix Coating on Cancer Cell Membrane-Encapsulated Polyethyleneimine/DNA Complexes for Efficient and Targeted DNA Delivery In Vitro. *mol. Pharm.* 2021, 18, 2803–2822. [CrossRef]
84. Cunha, V.R.R.; De Souza, R.B.; da Fonseca Martins, A.M.C.R.P.; Koh, I.H.J.; Constantino, V.R.L. Accessing the biocompatibility of layered double hydroxide by intramuscular implantation: Histological and microcirculation evaluation. *Sci. Rep.* **2016**, *6*, 30547. [CrossRef] [PubMed]

85. Shi, J.-J.; Ge, Y.-W.; Fan, Z.-H.; Li, Y.; Jia, W.-T.; Guo, Y.-P. Graphene oxide-modified layered double hydroxide/chitosan nacre-mimetic scaffolds treat breast cancer metastasis-induced bone defects. *Carbon* **2022**, *200*, 63–74. [CrossRef]